Multidrug resistance-associated protein 1

Description:

Description
  • Accession: P33527
  • Swissprot: MRP1_HUMAN
  • Organism: Homo sapiens
  • Gene: ABCC1
  • Target class: Transporter

Drug Relations:

anhydrovinblastine
Bioactivity details MOA
benzbromarone
Uricosuric that acts by increasing uric acid clearance. It is used in the treatment of gout. Bioactivity details MOA
ciclosporin
A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed). Bioactivity details MOA
colchicine
A major alkaloid from Colchicum autumnale L. and found also in other Colchicum species. Its primary therapeutic use is in the treatment of gout, but it has been used also in the therapy of familial Mediterranean fever (PERIODIC DISEASE). Bioactivity details MOA
daunorubicin
A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS. Bioactivity details MOA
daunorubicinol
main metabolite of daunomycin Bioactivity details MOA
diosmetin
a 5,7-dihydroxyflavone Bioactivity details MOA
doxorubicin
Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Bioactivity details MOA
etoposide
A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. Bioactivity details MOA
etravirine
HIV-1 reverse transriptase inhibitor; an anti-HIV agent Bioactivity details MOA
idarubicin
An orally administered anthracycline antineoplastic. The compound has shown activity against BREAST NEOPLASMS; LYMPHOMA; and LEUKEMIA. Bioactivity details MOA
imatinib
A tyrosine kinase inhibitor and ANTINEOPLASTIC AGENT that inhibits the BCR-ABL kinase created by chromosome rearrangements in CHRONIC MYELOID LEUKEMIA and ACUTE LYMPHOBLASTIC LEUKEMIA, as well as PDG-derived tyrosine kinases that are overexpressed in gastrointestinal stromal tumors. Bioactivity details MOA
indomethacin
A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES. Bioactivity details MOA
irinotecan
Irinotecan is a derivative of camptothecin. Camptothecins act as specific inhibitors of the enzyme DNA topoisomerase I. Irinotecan and its active metabolite SN-38 bind reversibly to the topoisomerase I-DNA complex and induce single-strand DNA lesions which block the DNA replication fork and are responsible for the cytotoxicity. Irinotecan is metabolized by carboxylesterase to SN-38. SN-38 is approximately 1000 times as potent as irinotecan as an inhibitor of topoisomerase I purified from human and rodent tumour cell lines. Bioactivity details MOA
methotrexate
An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA. Bioactivity details MOA
mezlocillin
Semisynthetic ampicillin-derived acylureido penicillin. It has been proposed for infections with certain anaerobes and may be useful in inner ear, bile, and CNS infections. Bioactivity details MOA
mitoxantrone
An anthracenedione-derived antineoplastic agent. Bioactivity details MOA
pimozide
A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to HALOPERIDOL for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug Evaluations Annual, 1994, p403) Bioactivity details MOA
quercetin
A flavonol widely distributed in plants. It is an antioxidant, like many other phenolic heterocyclic compounds. Glycosylated forms include RUTIN and quercetrin. Bioactivity details MOA
saquinavir
An HIV protease inhibitor which acts as an analog of an HIV protease cleavage site. It is a highly specific inhibitor of HIV-1 and HIV-2 proteases, and also inhibits CYTOCHROME P-450 CYP3A. Bioactivity details MOA
sulfinpyrazone
A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties. Bioactivity details MOA
verapamil
A calcium channel blocker that is a class IV anti-arrhythmia agent. Bioactivity details MOA
vinblastine
Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.) Bioactivity details MOA
vincristine
An antitumor alkaloid isolated from VINCA ROSEA. (Merck, 11th ed.) Bioactivity details MOA